Home   Business   Article

Subscribe Now

Nuformix files first cannabinoid cocrystal patent




Cannabidiol, or CBD, is just one part of a wider therapeutic landscape. Picture: Matthew Walker
Cannabidiol, or CBD, is just one part of a wider therapeutic landscape. Picture: Matthew Walker

Progress at Nuformix, the pharma development company which uses co-crystal technology to unlock the therapeutic potential of approved small molecule drugs, continues apace with the arrival of a lung fibrosis specialist to the advisory board and a first patent filing under the agreement with Ebers Tech of Canada.

The appointment of Dr Muhunthan Thillai to Nuformix’s scientific advisory board reflects progress made with Nuformix’s NXP002 programme as a treatment for idiopathic lung fibrosis (IPF) as it finalises its clinical development plans. Dr Thillai is the lead clinician for the Cambridge Interstitial Lung Disease Unit, where he is also a consultant.

Nuformix managing director Dan Gooding said: “I’m delighted to announce Dr Thillai’s appointment as he is a unique individual. Muhunthan has a complete understanding of IPF patients, from those newly diagnosed to those receiving lung transplants at end stage and runs the UK’s second largest IPF patient clinic at Royal Papworth.



This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies - Learn More